Publicaciones en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (44)

2024

  1. Evaluation of a quality improvement intervention to reduce anastomotic leak following right colectomy (EAGLE): pragmatic, batched stepped-wedge, cluster-randomized trial in 64 countries

    British Journal of Surgery, Vol. 111, Núm. 1

2023

  1. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 11, pp. 772-778

  2. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

2022

  1. New Antivirals and Immune Therapies for COVID-19 Infection

    Archivos de Bronconeumologia

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection

    BJS Open

  3. Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score

    British Journal of Surgery, Vol. 19, Núm. 4

2019

  1. Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: Retrospective analyses of two phase II randomised Spanish TTD trials

    ESMO Open, Vol. 4, Núm. 6

2018

  1. First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

    European Journal of Cancer, Vol. 101, pp. 263-272

2016

  1. Benchmarking en cirugía torácica. Tercera edición

    Archivos de Bronconeumologia, Vol. 52, Núm. 4, pp. 204-210

2015

  1. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: A phase II study of the Spanish cooperative group for the treatment of digestive tumours

    European Journal of Cancer, Vol. 51, Núm. 11, pp. 1371-1380

  2. Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02

    Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

  5. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: Relationship between skin rash and survival (Pantar study)

    Annals of Oncology, Vol. 23, Núm. 7, pp. 1919-1925

  6. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2011

  1. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD)

    Critical Reviews in Oncology/Hematology, Vol. 77, Núm. 1, pp. 78-84

  2. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178